REHOVOT, Israel, and BRIDGEWATER, N.J., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that it will report its financial results for the fourth quarter ended December 31, 2018, on Thursday, February 28, after the markets close. Foamix will host a conference call and webcast at 8:30 a.m. Eastern Time on Friday, March 1.
|Conference Call & Webcast|
|Friday, March 1st @ 8:30am Eastern Time|
|Replays, Available through March 15th:|
A replay will also be archived on the Company’s website at www.foamix.com promptly after the conference call.
Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Our leading clinical stage product candidates are FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne and FMX103, our novel minocycline foam for the treatment of rosacea. We continue to pursue research & development of our proprietary, innovative foam technologies for the treatment of various skin conditions. We currently have development and license agreements relating to our technology with various pharmaceutical companies including LEO Pharma A/S and others.
Foamix uses its website (www.Foamix.com) as a channel to distribute information about Foamix and its product candidates from time to time. Foamix may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Foamix’s website in addition to following its press releases, filings with the Securities & Exchange Commission, public conference calls, and webcasts.
Ilan Hadar, CFO
Foamix Pharmaceuticals Ltd.
U.S. Investor Relations
LifeSci Advisors, LLC
Elizabeth Tang, PhD
LifeSci Public Relations